PharmiWeb2h
Quotient Sciences Announces Installation of World's First GMP Biofoundry-in-a-Boxâ„¢ from Centillion Technology
Quotient Sciences, a leading global drug development and manufacturing accelerator, today announced the installation of Centillion’s™ proprietary Biofoundry-in-a-Box (BiaB™), the first multi-product ...
PharmiWeb2h
DuneGlass Capital Announces the Launch of Aviva Aesthetics: The Industry's Only Entrepreneur-Owned and Led Medical Aesthetics Platform
Aviva Aesthetics provides med spa owners with an alternative to private equity CHICAGO, IL and FULTON, MD / ACCESSWIRE / November 15, 2024 / DuneGlass Capital, a healthcare services-focused ...
PharmiWeb1h
Aflibercept-Biosimilar FYB203 / AHZANTIVE®/ Baiama® receives positive CHMP Opinion from EMA
Statement/Regulatory AdmissionAflibercept-Biosimilar FYB203 / AHZANTIVE®/ Baiama® receives positive CHMP Opinion from EMA15-Nov-2024 / 18:18 CET/CESTDisclosure of an inside information acc. to Article ...
PharmiWeb2h
THIRA Health Welcomes Patricia Charles-Heathers, Ph.D., MPA, as New Executive Director
Seasoned Behavioral Health Leader Joins THIRA Health, Strengthening Commitment to Comprehensive Mental Health Care for Women and AdolescentsBELLEVUE, WA / ACCESSWIRE / November 15, 2024 / THIRA Health ...
PharmiWeb6h
NanoViricides, Inc. Has Filed Its Quarterly Report…
SHELTON, CT / ACCESSWIRE / November 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the quarter ending September 30 ...
PharmiWeb5h
CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results
Primary analysis data in potentially pivotal GBM study with lead program, Berubicin, on track for the first half of 2025Company strengthens cash position to extend runway to fund operations beyond ...
PharmiWeb6h
Justera Health Announces Management Change
TORONTO, ON / ACCESSWIRE / November 15, 2024 / Justera Health Ltd. (CSE:VTAL)(OTC PINK:SCRSF) ("Justera"or the"Company") is pleased to announce the changes to the leadership to the Company.The Company ...
PharmiWeb6h
CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results
BEIJING, CHINA / ACCESSWIRE / November 15, 2024 / CASI Pharmaceuticals, Inc. (Nasdaq:CASI) ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company specializing in the development ...
PharmiWeb7h
Encision Reports Second Quarter Fiscal Year 2025 Results
BOULDER, CO / ACCESSWIRE / November 15, 2024 / Encision Inc. (OTC PINK:ECIA), a medical device company owning patented Active Electrode Monitoring (AEM®) Technology that prevents dangerous radiant ...
PharmiWeb8h
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease
Eisai Europe Ltd. and Biogen Inc. announced today that a positive opinion has been received from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) ...
PharmiWeb8h
UK missing opportunity to unlock medicines for severe conditions
A new report from the Office of Health Economics (OHE) reveals how NICE may be systematically undervaluing medicines for severe medical conditions, including terminal cancer, compared to how the ...
PharmiWeb8h
Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria
The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults and pediatric ...